Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?

Group 1 - Athira Pharma, Inc. (ATHA) is currently ranked 2 (Buy) in the Zacks Rank system, indicating strong potential for outperforming the market in the next one to three months [1] - The Zacks Consensus Estimate for ATHA's full-year earnings has increased by 8.2% over the past quarter, reflecting improved analyst sentiment and earnings outlook [2] - Year-to-date, ATHA has gained approximately 28%, significantly outperforming the average gain of 11.1% for stocks in the Medical group [2] Group 2 - Athira Pharma, Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 497 companies and is currently ranked 84 in the Zacks Industry Rank [3] - The Medical - Biomedical and Genetics industry has seen an average gain of 1.9% this year, indicating that ATHA is performing better than its industry peers [3] - HCA Healthcare, another notable stock in the Medical sector, has returned 41.5% year-to-date and is ranked 1 (Strong Buy) in the Zacks Rank [2][3]